The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
There is an unmet medical need to develop new therapies that are safer and potentially allow the treatment of a broader range of cancers. Inhibiting the immune checkpoints TIGIT and CD96 represents an opportunity that may parallel and indeed complement the activity and impact of other lymphocyte checkpoint inhibitors in human cancer (eg. PD1/PD-L1). While testing these as targets in mice we will also learn more about their ligand CD155 and their expression in human tumors.
Preclinical Development Of A Therapeutic Anticancer Antibody To C-Met
Funder
National Health and Medical Research Council
Funding Amount
$435,530.00
Summary
Many common cancers cannot be effectively treated. A range of these cancers (e.g. gastric and lung cancer) display the molecule c-Met on their cell surface. c-Met promotes tumour growth; therefore, blocking c-Met is a promising strategy for treating these cancers. However, no antibodies or drugs that target c-Met have been licensed. The therapeutics that are being developed to target c-Met all have considerable limitations. Thus, there is an opportunity to develop a 'best-in-class' therapeutic.
Cancer is now the number one killer of Australians and there is an unmet medical need to develop new therapies that are safe and maximize anti-cancer efficacy. Cancer immunotherapy now represents a new fourth pillar in cancer treatment to complement surgery, radiotherapy and chemo-/targeted therapies. This application aims to develop new therapeutic approaches to broaden the effectiveness of cancer immunotherapy and potentially allow the treatment of a broader range of cancers and patients.
The Development Of Store Operated Calcium Channel Monoclonal Antibody Inhibitors As A Therapeutic Option For Breast Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$230,753.00
Summary
Despite recent advances in the treatment of breast cancer, a significant proportion of women with this disease receive little benefit from currently available treatments and die from breast cancer. Hence, new therapies for the breast cancers with the poorest prognosis are needed. This grant exploits our earlier finding that a specific calcium channel is a likely therapeutic target for breast cancer. Funding from this grant will be used to develop an inhibitory monoclonal antibody to this target.
The Ludwig Institute is adopting a two prong approach in the fight against cancer. Ludwig scientists are developing improved and sensitive scanning methods to aid in the conduct of field trials of new anti-cancer antibodies. In addition, they are also developing new targeted anti-cancer antibodies with improved properties that have the ability to bind to tumours while sparing normal tissues. These drugs can either attack the cancer directly or be used to carry drugs to the target thereby shrinki ....The Ludwig Institute is adopting a two prong approach in the fight against cancer. Ludwig scientists are developing improved and sensitive scanning methods to aid in the conduct of field trials of new anti-cancer antibodies. In addition, they are also developing new targeted anti-cancer antibodies with improved properties that have the ability to bind to tumours while sparing normal tissues. These drugs can either attack the cancer directly or be used to carry drugs to the target thereby shrinking the tumour.Read moreRead less
Development Of A Humanised Antibody For Treatment Of Cancer And Stroke
Funder
National Health and Medical Research Council
Funding Amount
$400,142.00
Summary
The protein PDGF-CC has a critical role in blood vessel development, and is implicated in the development of cancer, and the debilitating consequences of acute stroke. Researchers in the Ludwig Institute for Cancer Research have developed novel anti-PDGF-CC antibodies. The research program proposed will generate data and clinical reagents that will enable a lead candidate anti-PDGF-CC antibody to be commercialised, and ultimately evaluated clinically in cancer and stroke patients.
Monoclonal antibodies, such as the breast cancer therapeutic Herceptin, have revolutionised the treatment of cancer and inflammatory conditions. Will over $30 billion sales in 2011, they have also spawned a growing biotech industry. We have a generated a highly specific monoclonal antibody, which has shown efficacy in models of disease. This project will further advance and develop this monoclonal, allowing us to initiate clinical studies in patients.
Targeted Alpha Therapy For Metastatic Breast Cancer Using Alpha-Herceptin
Funder
National Health and Medical Research Council
Funding Amount
$332,420.00
Summary
The specific aim of this proposal is to demonstrate, in non-human primates, proof–of-concept of a patented new platform vaccine technology (scrambled antigen vaccine or SAVINE) designed to encode all the protein sequences of an infectious agent, in this case HIV-1. These are arranged as equal-sized, overlapping fragments such that all potential T cell epitopes that are needed to induce broad T-cell-mediated immunity are maintained. The synthetically designed vaccine uses consensus sequences of H ....The specific aim of this proposal is to demonstrate, in non-human primates, proof–of-concept of a patented new platform vaccine technology (scrambled antigen vaccine or SAVINE) designed to encode all the protein sequences of an infectious agent, in this case HIV-1. These are arranged as equal-sized, overlapping fragments such that all potential T cell epitopes that are needed to induce broad T-cell-mediated immunity are maintained. The synthetically designed vaccine uses consensus sequences of HIV-1 to provide universal coverage of the major HIV-1 strains for a global population. The synthetic systematically designed HIV-1 vaccine will be delivered using our newly developed prime-boost immunisation regime that induces particularly high levels of cell-mediated immunity.Read moreRead less
Sortase Peptide Technology: Enzymatic Site-specific Bioconjugation To Improve Antibody Drug Conjugate Production And Performance
Funder
National Health and Medical Research Council
Funding Amount
$402,046.00
Summary
Cancer is characterised by uncontrolled cell growth, leading to invasion and destruction of adjacent tissues. It is a major cause of death in Australia. Targeted drug delivery is an attractive therapeutic strategy that has the potential to lower systemic drug concentrations and reduce side effects. We are developing more efficient cancer drugs.
A New Therapeutic Monoclonal Antibody Targeting CD302 In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
This project will develop a new antibody treatment for Acute Myeloid Leukaemia. Antibody treatments help the body to attack the leukaemia using its immune system. The prognosis of this leukaemia is poor. Our current treatments use high dose chemotherapy and sometimes a stem cell transplant. Many patients cannot have the current therapy due to their age or other medical problems. A new antibody therapy may be used on its own or with other therapies to help more patients achieve remission.